As Braeburn Pharmaceuticals Inc. nears the finish line in the race to bring a buprenorphine injection to market for opioid use disorder (OUD) with a US FDA approval decision for its CAM2038 expected by Jan. 19, company executives are optimistic about the drug's prospects, including the therapy's eight proposed doses.
Scrip spoke with Princeton, NJ-based Braeburn's President and CEO Mike Derkacz as well as Chief Financial Officer David McIntyre in...






